Oligoclonal IgM bands are a promising biomarker for long-term cognitive outcomes in multiple sclerosis.

Humans Multiple Sclerosis / complications Oligoclonal Bands / cerebrospinal fluid Immunoglobulin M Cognition Neuropsychological Tests
Biomarker Cognition Cognitive impairment Lipid-specific oligoclonal IgM bands Multiple sclerosis

Journal

Multiple sclerosis and related disorders
ISSN: 2211-0356
Titre abrégé: Mult Scler Relat Disord
Pays: Netherlands
ID NLM: 101580247

Informations de publication

Date de publication:
Dec 2022
Historique:
received: 14 10 2022
revised: 20 10 2022
accepted: 03 11 2022
entrez: 22 12 2022
pubmed: 23 12 2022
medline: 24 12 2022
Statut: ppublish

Résumé

The presence of lipid-specific oligoclonal IgM bands (LS-OCMB) in cerebrospinal fluid is associated with a more severe clinical multiple sclerosis (MS) course. To investigate LS-OCMB as a prognostic biomarker of cognitive long-term outcomes in MS. Ninety-nine patients underwent neuropsychological assessment. Cognitive performance between LS-OCMB- and LS-OCMB+ patients was compared adjusting by age, education, anxiety-depression, disease duration, and disability. LS-OCMB+ patients of ∼13 years of disease duration performed worse on Symbol Digit Modalities Test (SDMT) (p = 0.005). LS-OCMB+ perform worse on information processing speed and working memory (SDMT), suggesting that LS-OCMB could be a useful biomarker for long-term cognitive outcomes.

Sections du résumé

BACKGROUND BACKGROUND
The presence of lipid-specific oligoclonal IgM bands (LS-OCMB) in cerebrospinal fluid is associated with a more severe clinical multiple sclerosis (MS) course.
OBJECTIVE OBJECTIVE
To investigate LS-OCMB as a prognostic biomarker of cognitive long-term outcomes in MS.
METHODS METHODS
Ninety-nine patients underwent neuropsychological assessment. Cognitive performance between LS-OCMB- and LS-OCMB+ patients was compared adjusting by age, education, anxiety-depression, disease duration, and disability.
RESULTS RESULTS
LS-OCMB+ patients of ∼13 years of disease duration performed worse on Symbol Digit Modalities Test (SDMT) (p = 0.005).
CONCLUSION CONCLUSIONS
LS-OCMB+ perform worse on information processing speed and working memory (SDMT), suggesting that LS-OCMB could be a useful biomarker for long-term cognitive outcomes.

Identifiants

DOI: 10.1016/j.msard.2022.104397 PMID: 36544326
pubmed: 36544326
pii: S2211-0348(22)00901-4
doi: 10.1016/j.msard.2022.104397
pii:
doi:

Substances chimiques

Oligoclonal Bands 0
Immunoglobulin M 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

104397

Informations de copyright

Copyright © 2022. Published by Elsevier B.V.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The author(s) declared the following potential conflicts of interest with respect to the research, authorship and/ or publication of this article: C.C.M: has received support for attending congresses from sanofi, merk, teva and novartis. E.Q: has nothing to disclose. M.B: has nothing to disclose. J.S.P: has nothing to disclose. L.G: has nothing to disclose. A.Q.V: has nothing to disclose. L.C.F: has received compensation for consulting services and speaking fees from Biogen, Novartis, Bayer, Merck, Sanofi, Janssen, Roche, Bristol Myers Squibb, TEVA and Almirall. LM.V: Received com compensation for consulting services and speaking fees from Biogen, Novartis, Merck, Sanofi, Genzyme, Roche, and Bristol Myers Squibb, Almirall. E.F.D: has received compensation for consulting services and/or speaking fees from Almirall, Biogen, Merck, Roche and Sanofi-Genzyme. J.G: has received compensation for consulting services and speaking fees from Biogen, Novartis, Merck, Sanofi, Genzyme, Roche and TEVA. Y.A: has received funding for research projects or in the form of conference fees, mentoring, and assistance for conference attendance from: Bayer, Biogen, Roche, Merck, Novartis, Allmirall and Sanofi-Genzime and Bristol Myers Squibb. A.M.B: has nothing to disclose. M.C: has nothing to disclose. L.R.T: has received compensation for consulting services and speaking fees from Biogen, Novartis, Bayer, Merck, Sanofi, Genzyme, Roche, Bristol Myers Squibb, TEVA and Almirall. J.G.F: has received speaking fees from Novartis, Teva, Sanofi and Merck.

Auteurs

Clàudia Coll-Martinez (C)

Girona Neuroimmumology and Multiple Sclerosis Unit, Neurology Department, Dr. Josep Trueta University Hospital and Santa Caterina Hospital, Dr Castany s/n, Girona, Salt 17190, Spain; Neurodegeneration and Neuroinflammation Research Group, Girona Biomedical Research Institute (IDIBGI), Salt, Spain; Redes de Investigación Cooperativa Orientada a Resultados en Salud (RICORS), Red de Enfermedades inflamatorias (RD21/0002/0063), Instituto de Salud Carlos III, Madrid, Spain.

Ester Quintana (E)

Neurodegeneration and Neuroinflammation Research Group, Girona Biomedical Research Institute (IDIBGI), Salt, Spain.

Maria Buxó (M)

Girona Biomedical Research Institute (IDIBGI), Salt, Spain.

Judit Salavedra-Pont (J)

Girona Neuroimmumology and Multiple Sclerosis Unit, Neurology Department, Dr. Josep Trueta University Hospital and Santa Caterina Hospital, Dr Castany s/n, Girona, Salt 17190, Spain; Neurodegeneration and Neuroinflammation Research Group, Girona Biomedical Research Institute (IDIBGI), Salt, Spain.

Laia Gasull-Vicens (L)

Girona Neuroimmumology and Multiple Sclerosis Unit, Neurology Department, Dr. Josep Trueta University Hospital and Santa Caterina Hospital, Dr Castany s/n, Girona, Salt 17190, Spain.

Ana Quiroga-Varela (A)

Neurodegeneration and Neuroinflammation Research Group, Girona Biomedical Research Institute (IDIBGI), Salt, Spain; Redes de Investigación Cooperativa Orientada a Resultados en Salud (RICORS), Red de Enfermedades inflamatorias (RD21/0002/0063), Instituto de Salud Carlos III, Madrid, Spain.

Lucienne Costa-Frossard (L)

Redes de Investigación Cooperativa Orientada a Resultados en Salud (RICORS), Red de Enfermedades inflamatorias (RD21/0002/0063), Instituto de Salud Carlos III, Madrid, Spain; Neurology Department, Ramon y Cajal University Hospital, Madrid, Spain; Universidad de Alcalá, Madrid, Spain; Multiple Sclerosis Group, Instituto Ramón y Cajal de investigación Sanitaria (IRYCIS), Madrid, Spain.

Luisa María Villar (LM)

Redes de Investigación Cooperativa Orientada a Resultados en Salud (RICORS), Red de Enfermedades inflamatorias (RD21/0002/0063), Instituto de Salud Carlos III, Madrid, Spain; Multiple Sclerosis Group, Instituto Ramón y Cajal de investigación Sanitaria (IRYCIS), Madrid, Spain; Immunology Department, Ramon y Cajal University Hospital, Madrid, Spain.

Eva Fernández-Díaz (E)

Neurology Department, Albacete University Hospital Albacete, Spain.

Julia Gracia (J)

Neurology Department, Albacete University Hospital Albacete, Spain.

Yolanda Aladro (Y)

Redes de Investigación Cooperativa Orientada a Resultados en Salud (RICORS), Red de Enfermedades inflamatorias (RD21/0002/0063), Instituto de Salud Carlos III, Madrid, Spain; Neurology Department, Getafe University Hospital, Madrid, Spain; Universidad Europea de Madrid, Madrid, Spain.

Alejandro Méndez-Burgos (A)

Neurology Department, Getafe University Hospital, Madrid, Spain; Universidad Europea de Madrid, Madrid, Spain.

Marta Cerezo (M)

Neurology Department, Getafe University Hospital, Madrid, Spain; Universidad Complutense de Madrid, Madrid, Spain.

Lluís Ramió-Torrentà (L)

Girona Neuroimmumology and Multiple Sclerosis Unit, Neurology Department, Dr. Josep Trueta University Hospital and Santa Caterina Hospital, Dr Castany s/n, Girona, Salt 17190, Spain; Neurodegeneration and Neuroinflammation Research Group, Girona Biomedical Research Institute (IDIBGI), Salt, Spain; Redes de Investigación Cooperativa Orientada a Resultados en Salud (RICORS), Red de Enfermedades inflamatorias (RD21/0002/0063), Instituto de Salud Carlos III, Madrid, Spain; Medical Sciences Department, University of Girona, Girona, Spain. Electronic address: llramio.girona.ics@gencat.cat.

Jordi Gich (J)

Girona Neuroimmumology and Multiple Sclerosis Unit, Neurology Department, Dr. Josep Trueta University Hospital and Santa Caterina Hospital, Dr Castany s/n, Girona, Salt 17190, Spain; Neurodegeneration and Neuroinflammation Research Group, Girona Biomedical Research Institute (IDIBGI), Salt, Spain; Medical Sciences Department, University of Girona, Girona, Spain. Electronic address: jgich.girona.ics@gencat.cat.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Oligoclonal IgM bands are a promising...
questionsmedicales.fr › Maladies du système immunitaire › Maladies auto-immunes › Maladies auto-immunes du système nerveux › Maladies démyélinisantes auto-immunes du SNC › Sclérose en plaques › Oligoclonal IgM bands are a promising...
questionsmedicales.fr › Facteurs biologiques › Marqueurs biologiques › Bandes oligoclonales › Oligoclonal IgM bands are a promising...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Isotypes des immunoglobulines › Immunoglobuline M › Oligoclonal IgM bands are a promising...
questionsmedicales.fr › Phénomènes psychologiques › Processus mentaux › Cognition › Oligoclonal IgM bands are a promising...
questionsmedicales.fr › Disciplines et activités comportementales › Tests psychologiques › Tests neuropsychologiques › Oligoclonal IgM bands are a promising...